Company: IMRX
Filing Date: 2025-04-21
Form Type: DEF 14A
Source: 0001790340-25-000053
Chunk: 37

Company: Immuneering Corp
Filing Date: 2025-04-21
Form: DEF 14A
Chunk 37
---
 common stock with an exercise price per share greater than $3.01 that were held by current employees and certain non-employee service providers under the 2021 Plan (the “Eligible Options”), including options held by Michael D. Bookman. Mr. Bookman held an aggregate of 384,416 Eligible Options with original exercise prices ranging from $4.25 to $15.00. Options held by our other named executive officers and by the non-employee members of the Board were not eligible for the repricing.

As a result of the repricing, as of the Repricing Effective Date, the exercise price of all Eligible Options, including those held by Mr. Bookman, was reduced to $3.01 per share, which represented approximately two times the closing trading price of our Class A common stock on the Nasdaq Global Market on the Repricing Effective Date; however, the

<div align='center'>25</div>

TABLE OF CONTENTS

exercise price for the repriced options will revert to the applicable original exercise price for any exercise occurring prior to June 30, 2025 (the “Retention Period”), unless there is a change of control of the Company or the option holder’s employment has been terminated (i) by us without cause, or (ii) by reason of death or disability. The repriced options otherwise remain subject to their existing terms and conditions as set forth in the 2021 Plan and applicable award agreements.

To the extent a repriced option of Mr. Bookman’s is exercised prior to the Retention Period End Date (as defined below), or Mr. Bookman’s employment terminates prior to the Retention Period End Date, Mr. Bookman will be required to pay the original exercise price per share of the repriced options. The “Retention Period End Date” means the earliest of: (i) June 30, 2025; (ii) the date of a change of control of the Company; (iii) the date that Mr. Bookman’s employment has been terminated by us without cause; or (iv) the date that Mr. Bookman’s employment has been terminated by reason of his death or disability.

Our compensation committee reviewed and discussed the repricing and after multiple meetings recommended approval to the Board. The Board then approved the repricing after careful consideration of various alternatives, and a review of other applicable factors with the input of the compensation committee’s independent compensation consultant. The Board designed the repricing, with the original exercise price applicable during the Ret